KYRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Kyra, and when can generic versions of Kyra launch?
Kyra is a drug marketed by Sun Pharm and is included in one NDA.
The generic ingredient in KYRA is drospirenone; ethinyl estradiol. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kyra
A generic version of KYRA was approved as drospirenone; ethinyl estradiol by DR REDDYS LABS SA on September 7th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KYRA?
- What are the global sales for KYRA?
- What is Average Wholesale Price for KYRA?
Summary for KYRA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | KYRA at DailyMed |
US Patents and Regulatory Information for KYRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | KYRA | drospirenone; ethinyl estradiol | TABLET;ORAL | 202318-001 | Jul 23, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
